@article{9111d66981e349afba7cd55f5bdf53ab,
title = "COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies: British Journal of Haematology",
abstract = "COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04–11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11–1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients. {\textcopyright} 2021 The Authors.British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",
keywords = "Covid-19, leukemia, lymphoma, myeloma, SARS-CoV-2, immunoglobulin G, virus antibody, adult, aged, antibody response, Article, cancer immunotherapy, clinical feature, coronavirus disease 2019, female, hematologic malignancy, human, major clinical study, male, patient care, polymerase chain reaction, risk factor, seroconversion, treatment withdrawal, antibody production, clinical trial, complication, hematologic disease, immunology, middle aged, very elderly, young adult, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Antibody Formation, COVID-19, Female, Hematologic Neoplasms, Humans, Immunoglobulin G, Male, Middle Aged, Seroconversion, Young Adult",
author = "F. Passamonti and A. Romano and M. Salvini and F. Merli and M.G.D. Porta and R. Bruna and E. Coviello and I. Romano and R. Cairoli and R. Lemoli and F. Farina and A. Venditti and A. Busca and M. Ladetto and M. Massaia and A. Pinto and L. Arcaini and A. Tafuri and F. Marchesi and N. Fracchiolla and M. Bocchia and D. Armiento and A. Candoni and M. Krampera and M. Luppi and V. Cardinali and S. Galimberti and C. Cattaneo and {La Barbera}, E.O. and R. Mina and F. Lanza and G. Visani and P. Musto and L. Petrucci and F. Zaja and P.A. Grossi and L. Bert{\`u} and L. Pagano and P. Corradini and E. Derenzini and M. Marchetti and A.M. Scattolin and A. Corso and P. Tosi and F. Gherlinzoni and C.G. Passerini and M. Cavo and C. Fava and M. Turrini and C. Visco and P. Zappasodi and M. Merli and B. Mora and A.M. Vannucchi and Investigators*, {the ITA-HEMA-COV}",
note = "Cited By :9 Export Date: 14 February 2022 CODEN: BJHEA Correspondence Address: Passamonti, F.; Dipartimento di Medicina e Chirurgia, Italy; email: francesco.passamonti@uninsubria.it Chemicals/CAS: immunoglobulin G, 97794-27-9; Antibodies, Viral; Immunoglobulin G Funding details: Ministero della Salute Funding details: Ministero dell{\textquoteright}Istruzione, dell{\textquoteright}Universit{\`a} e della Ricerca, MIUR, 2017WXR7ZT Funding text 1: The study has been supported by the charity AIL (Associazione italiana contro le leucemie‐linfomi e mieloma) Onlus of Varese, by grants from the Ministero della Salute, Rome, Italy (Finalizzata 2018, NET‐2018‐12365935, Personalized medicine program on myeloid neoplasms: characterization of the patient's genome for clinical decision making and systematic collection of real world data to improve quality of health care), by grants from the Ministero dell{\textquoteright}Istruzione, dell{\textquoteright}Universit{\`a} e della Ricerca, Roma, Italy (PRIN 2017, 2017WXR7ZT; Myeloid Neoplasms: an integrated clinical, molecular and therapeutic approach) and by grants from Fondazione Matarelli, Milan. References: Passamonti, F., Cattaneo, C., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020) Lancet Haematol, 7 (10), pp. e737-e745; Vijenthira, A., Gong, I.Y., Fox, T.A., Booth, S., Cook, G., Fattizzo, B., Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients (2020) Blood, 136 (25), pp. 2881-2892; Chari, A., Samur, M.K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K., Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) Blood, 136 (26), pp. 3033-3040; Mato, A.R., Roeker, L.E., Lamanna, N., Allan, J.N., Leslie, L., Pagel, J.M., Outcomes of COVID-19 in patients with CLL: a multicenter international experience (2020) Blood, 136 (10), pp. 1134-1143; Regalado-Artamendi, I., Jim{\'e}nez-Ubieto, A., Hern{\'a}ndez-Rivas, J.{\'A}., Navarro, B., N{\'u}{\~n}ez, L., Alaez, C., Et, A., Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study (2021) Hemasphere, 5 (3); Sharma, A., Bhatt, N.S., St Martin, A., Abid, M.B., Bloomquist, J., Chemaly, R.F., Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study (2021) Lancet Haematol, 8 (3), pp. e185-e193; Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Antibody responses to SARS-CoV-2 in patients with COVID-19 (2020) Nat Med, 26 (6), pp. 845-848; Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019 (2020) Clin Infect Dis, 71 (16), pp. 2027-2034; Roeker, L.E., Knorr, D.A., Pessin, M.S., Ramanathan, L.V., Thompson, M.C., Leslie, L.A., Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia (2020) Leukemia, 34 (11), pp. 3047-3049; O{\textquoteright}Nions, J., Muir, L., Zheng, J., Rees-Spear, C., Rosa, A., Roustan, C., SARS-CoV-2 antibody responses in patients with acute leukaemia (2021) Leukemia, 35 (1), pp. 289-292; Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia (2021) Blood, 137 (23), pp. 3165-3173; Ainsworth, M., Andersson, M., Auckland, K., Baillie, J.K., Barnes, E., Beer, S., Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison (2020) Lancet Infect Dis, 20 (12), pp. 1390-1400; van Dam, P., Huizing, M., Roelant, E., Hotterbeekx, A.N., De Winter, F.H.R., Kumar-Singh, S., Immunoglobin G/total antibody testing for SARS-CoV-2: a prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests (2021) Eur J Cancer, 148, pp. 328-339; Aydillo, T., Gonzalez-Reiche, A.S., Aslam, S., van de Guchte, A., Khan, Z., Obla, A., Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer (2020) N Engl J Med, 383 (26), pp. 2586-2588; Bird, P.W., Badhwar, V., Kennedy, B., Ladani, S., Tang, J.W., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients (2021) J Med Virol, 93 (7), pp. 4585-4591",
year = "2021",
doi = "10.1111/bjh.17704",
language = "English",
volume = "195",
pages = "371--377",
journal = "Br. J. Haematol.",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "3",
}